Codexis Unveils ECO Synthesis™ Platform for Large-Scale RNAi Therapeutics Production at TIDES USA
May 10 2023 - 4:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced the unveiling of its Enzyme-Catalyzed
Oligonucleotide (ECO) Synthesis™ technology, a proprietary new
synthesis platform being developed for manufacturing RNA
oligonucleotide therapeutics at scale. The ECO Synthesis™
technology was unveiled during a pre-conference workshop at the
TIDES USA annual meeting, being held May 7-10, 2023, in San Diego,
CA.
Ribonucleic acid (RNA) as a therapeutic modality has gained
tremendous traction in recent years with the growing number of
messenger RNA (mRNA) vaccines and small interfering RNA (siRNA)
product candidates advancing in clinical studies. However,
large-scale production faces complex challenges in nucleic acids
quality and quantity, as well as overall economics. By replacing
phosphoramidite chemistry with enzymatic methods, Codexis’
proprietary ECO Synthesis™ technology is specifically engineered to
overcome these difficulties to enable scalable and sustainable
manufacturing.
“At TIDES, we were pleased to introduce our ECO Synthesis™
platform, an enzymatic solution with the potential to enable truly
scalable RNAi therapeutics production,” said Stephen Dilly, MBBS,
PhD, President and Chief Executive Officer of Codexis. “As
RNA-based therapeutics are applied to larger disease indications,
we believe the current route of chemical synthesis will rapidly
become unsustainable, and our customers have already voiced the
need for an enzymatic option to manufacture siRNA. Between our long
history of engineering increasingly complex enzymes for
Pharmaceutical Manufacturing and our existing base of relevant
customer relationships, we are uniquely positioned for success in
this emerging market. We are well on our way toward developing the
suite of enzymes necessary for the full platform, and we look
forward to reporting further progress at scientific meetings later
this year.”
The TIDES presentation slides are available on the ‘News &
Events’ page within the Investor Relations section of the Codexis
website at https://www.codexis.com/investors/news-events; a video
recording of the ECO Synthesis™ portion of the TIDES presentation
will be made available in the same location. More information on
the Company’s novel ECO Synthesis™ technology can be found on the
Codexis website at
www.codexis.com/technology/eco-synthesis-technology.
About Codexis
Codexis is a leading enzyme engineering company leveraging its
proprietary CodeEvolver® technology platform to discover, develop
and enhance novel, high-performance enzymes and other classes of
proteins. Codexis enzymes solve for real-world challenges
associated with small molecule pharmaceuticals manufacturing,
nucleic acid synthesis and genomic sequencing, and – as
biotherapeutic candidates – they have the potential to treat
challenging diseases. Codexis’ unique enzymes can drive
improvements such as higher yields, reduced energy usage and waste
generation, improved efficiency in manufacturing, greater
sensitivity in genomic and diagnostic applications and potentially
more efficacious therapeutics. For more information,
visit www.codexis.com.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Codexis, they
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements regarding how engineered enzymes, including Codexis’ ECO
Synthesis™ technology, have the potential to enable scalable and
sustainable manufacturing of mRNA vaccines and siRNA product
candidates, whether the current route of chemical synthesis will
rapidly become unsustainable for the manufacturing of RNA-based
therapeutics and Codexis’ ability to develop a suite of enzymes
necessary for having full platform. You should not place undue
reliance on these forward-looking statements because they involve
known and unknown risks, uncertainties and other factors that are,
in some cases, beyond Codexis’ control and that could materially
affect actual results. Additional information about factors that
could materially affect actual results can be found in Codexis’
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (“SEC”) on May 4, 2023, including under the
caption “Risk Factors,” and in Codexis’ other periodic reports
filed with the SEC. Codexis expressly disclaims any intent or
obligation to update these forward-looking statements, except as
required by law.
For More Information
Investor ContactCarrie McKim(336) 608-9706ir@codexis.com
Media ContactLauren Musto(781) 572-1147media@codexis.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024